COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00221403
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : June 27, 2011
Stanley Medical Research Institute
Information provided by:
Children's Hospital Medical Center, Cincinnati

Brief Summary:
The primary aim of this proposal is to conduct a preliminary controlled trial of valproate and risperidone in children ages 3-7 yr. with bipolar disorders. A secondary aim is to carefully characterize these subjects using clinical rating scales and develop pilot data on a very young cohort of children with bipolar disorders that can be used to support an application to NIMH for a prospective, longitudinal study that will provide important information about the course, medication response, neurobiology and outcome of these patients.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Drug: Risperidone Valproate Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders
Study Start Date : September 2004
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder

Intervention Details:
  • Drug: Risperidone Valproate
    liquid, BID dosing.

Primary Outcome Measures :
  1. YMRS & CGI-I [ Time Frame: 6 weeks ]
  2. YMRS [ Time Frame: 6 Weesk ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 7 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients, 3-7 years 11 months of age.
  2. Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.
  3. Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) bipolar disorder and must currently display an acute manic, hypomanic or mixed episode as determined by DSM-IV criteria. This includes the following diagnoses: 296.4x, Bipolar I Disorder, Most Recent Episode Manic; 296.6x, Bipolar I Disorder, Most recent Episode Mixed; and 296.0x, Bipolar I Disorder, Single Manic Episode, Bipolar II Disorder, Most Recent Episode Hypomanic.
  4. Patients must have an initial score (at day 0) on the YMRS total score of at least 20.
  5. Subjects and their caretakers should be fluent in English.

Exclusion Criteria:

  1. Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions.
  2. Neurologic disorders including epilepsy, stroke, or severe head trauma.
  3. Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, urinalysis, thyroid indices (T3, Total T4, Free T4, TSH), and EKG.
  4. Mania due to a general medical condition or substance-induced mania (DSM-IV).
  5. Mental retardation (IQ <70), evidence of Fetal Alcohol Syndrome or an Alcohol-Related Neurodevelopmental Disorder.
  6. History of hypersensitivity to or intolerance of risperidone or valproate.
  7. Prior history of risperidone or valproate non-response.
  8. Judged clinically to be at serious suicidal risk.
  9. Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry.
  10. Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00221403

Layout table for location information
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45267
United States, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53201
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Stanley Medical Research Institute
Layout table for investigator information
Principal Investigator: Robert A Kowatch, MD University of Cincinnati

Layout table for additonal information
Responsible Party: Robert A. Kowatch, CCHMC Identifier: NCT00221403    
Other Study ID Numbers: 03-12-26
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: June 2011
Keywords provided by Children's Hospital Medical Center, Cincinnati:
bipolar disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Pathologic Processes
Bipolar and Related Disorders
Mental Disorders
Valproic Acid
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Enzyme Inhibitors
GABA Agents
Antimanic Agents